2. Academic Validation
  3. Antiangiogenic Pterocarpan and Flavonoid Constituents of Erythrina lysistemon

Antiangiogenic Pterocarpan and Flavonoid Constituents of Erythrina lysistemon

  • J Nat Prod. 2023 Apr 28;86(4):759-766. doi: 10.1021/acs.jnatprod.2c00909.
Sarah M Nassief 1,  Masouda E Amer 1,  Eman Shawky 1,  Kamakshi Sishtla 2,  Eduard Mas-Claret 3 4,  Anbukkarasi Muniyandi 2,  Timothy W Corson 2 5,  Dulcie A Mulholland 3,  Sawsan El-Masry 1
Affiliations

Affiliations

  • 1 Department of Pharmacognosy, Faculty of Pharmacy, University of Alexandria, Alkhartoom Square, Alexandria 21521, Egypt.
  • 2 Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, 1160 W. Michigan St., Indianapolis, Indiana 46202, United States.
  • 3 Natural Products Research Group, Department of Chemistry, Faculty of Engineering and Physical Sciences, University of Surrey, Guildford GU2 7XH, United Kingdom.
  • 4 Royal Botanic Gardens, Kew, Kew Green, Richmond TW9 3AE, United Kingdom.
  • 5 Department of Pharmacology and Toxicology, Indiana University School of Medicine, 1160 West Michigan Street, Indianapolis, Indiana 46202, United States.
PMID: 36938984 DOI: 10.1021/acs.jnatprod.2c00909
Abstract

The roots of Erythrina lysistemon, growing in Egypt, yielded 24 flavonoid compounds, including 17 pterocarpans, two Isoflavanones, one flavanone, two isoflavans, one 2-arylbenzofuran, and an isoflava-3-ene. Nine pterocarpans have not been reported previously (7-9, 11-14, 19, and 20), and 11 are reported here for the first time from this species. Structures were established using HRESIMS, NMR, and circular dichroism techniques. Selected compounds were tested for their ability to block the growth of human retinal endothelial cells and antiangiogenic activity in vitro. The isoflavonoids 5 and 6, and the pterocarpans 1, 2, 4, 20, and 22 demonstrated selective antiproliferative activities on endothelial cells compared to a nonendothelial cell type, with concentration-dependent antiangiogenic effects in vitro against HRECs, a cell type relevant to neovascular eye diseases.

Figures